ArticlePain2016

Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.

Jennifer Y Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.